Patrys forms advisory committee for RLS-2202 injectable development
Patrys (ASX:PAB) established a clinical advisory committee to guide development of quetiapine injectable formulation RLS-2202 for treating delirium in acute-care settings, drawing acute and critical care expertise from Australia, the US, and Europe.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.